Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer

被引：0
|
作者：
Barnato, Sara E.
Jeruss, Jacqueline Sara
Bethke, Kevin P.
Hansen, Nora M.
Khan, Seema Ahsan
Von Roenn, Jamie H.
Rosen, Steven T.
Gradishar, William John
Siziopikou, Kalliopi P.
Meservey, Caitlin
Kaklamani, Virginia G.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Lynn Sage Comprehens Breast Ctr, Chicago, IL USA
[3] Lynn Sage Comprehens Canc Ctr, Chicago, IL USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1134
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
    Tanaka, N.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Jibiki, N.
    Yukawa, H.
    Matsuoka, A.
    Kodera, A.
    Kamimura, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [32] Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
    Norikazu Masuda
    Hiroko Bando
    Takashi Yamanaka
    Takayuki Kadoya
    Masato Takahashi
    Shigenori E. Nagai
    Shoichiro Ohtani
    Tomoyuki Aruga
    Eiji Suzuki
    Yuichiro Kikawa
    Hiroyuki Yasojima
    Hiroi Kasai
    Hiroshi Ishiguro
    Hidetaka Kawabata
    Satoshi Morita
    Hironori Haga
    Tatsuki R. Kataoka
    Ryuji Uozumi
    Shinji Ohno
    Masakazu Toi
    Breast Cancer Research and Treatment, 2021, 188 : 117 - 131
  • [33] Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
    Masuda, Norikazu
    Bando, Hiroko
    Yamanaka, Takashi
    Kadoya, Takayuki
    Takahashi, Masato
    Nagai, Shigenori E.
    Ohtani, Shoichiro
    Aruga, Tomoyuki
    Suzuki, Eiji
    Kikawa, Yuichiro
    Yasojima, Hiroyuki
    Kasai, Hiroi
    Ishiguro, Hiroshi
    Kawabata, Hidetaka
    Morita, Satoshi
    Haga, Hironori
    Kataoka, Tatsuki R.
    Uozumi, Ryuji
    Ohno, Shinji
    Toi, Masakazu
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (01) : 117 - 131
  • [34] A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC)
    Bagegni, Nusayba Ali
    Nehring, Leslie
    Anderson, Jill
    Haas, Brittney
    Luo, Jingqin
    Trivedi, Meghna S.
    Kennedy, Laura Carpin
    Bhave, Manali A.
    Daily, Karen Colleen
    Razaq, Wajeeha
    Lu, Yiling
    Wang, Wei-Lien
    Wulf, Gerburg M.
    Said, Rabih
    Ma, Cynthia X.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Neoadjuvant eribulin in early triple negative breast cancer
    Naito, Y.
    Yonemori, K.
    Yamamoto, H.
    Takahashi, M.
    Nakamura, R.
    Masuda, N.
    Aogi, K.
    Yamanaka, T.
    Ito, Y.
    Yoshida, A.
    Tsuda, H.
    Kuchiba, A.
    Hata, T.
    Tamura, K.
    Fujiwara, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S97 - S98
  • [36] RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial
    Singh, Jasmeet Chadha
    Stein, Stacy
    Volm, Matthew
    Smith, Julia Anne
    Adams, Sylvia
    Meyers, Marlene
    Speyer, James L.
    Novik, Yelena
    Schneider, Robert
    Formenti, Sylvia
    Muggia, Franco
    Jhaveri, Komal L.
    Goldberg, Judith D.
    Heese, Scott
    Li, Xiaochun
    Davis, Samantha
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    CANCER RESEARCH, 2017, 77
  • [38] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Diab, Sami
    CANCER RESEARCH, 2018, 78 (04)
  • [39] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Young, Louise
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 176 - 176
  • [40] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S16 - S16
12345